Medicine Inpatient basal bolus regimens| Insulin Glargine/Lispro versus Insulin NPH/Regular. Retrospective comparison of hypoglycemic rates and glucose controland the differential effect of non-clinical temporal factors on them RUSH UNIVERSITY Leon FogelfeldJohn Somberg Guerra PerrinYannis SergioObjective: Inpatient protocols for glycemic controlGuerra PerrinY...
Glargine insulin is a long-acting insulin which has no pronounced peak and which does provide 24-hour of basal insulin supply. To mention that higher doses, particularly of regular or NPH insulin, prolong the duration of action. Table 2.4. Pharmacodynamics of Currently Available Insulin ...
Insulin glargine 300 U/mL (Gla-300) and insulin degludec 100 U/mL (Deg-100) are long-acting basal insulin products, both shown to have prolonged and more stable PK and PD profiles when compared with insulin glargine 100 U/mL (Gla-100) [3], [4]. In phase 3 clinical treat-to-target...
Clinical trials have shown that insulin analogues, such as glargine, detemir, aspart, and lispro, do not offer major advantages over human insulin products, such as neutral protamine Hagedorn (NPH) and regular human insulin, for patients with type 2 diabetes.1,2 In these studies, nei...
regular human insulin or rapid-acting insulin analogues for oral therapy. In people with type 2 diabetes, orally administered OI338 had an elimination plasma half-life of 70 h at pharmacokinetic steady state and a relative bio-efficacy of 1.7% compared to SC administered insulin glargine, with...
A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment)...
although a significant reduction in HbA1c could have been observed in the insulin glargine group with a larger sample size. This study demonstrated that I-338 is a promising candidate for oral basal insulin, comparable to the established insulin glargine. With respect to the safety profile, the ...
Both types are considered safe and effective; however, there may be less interindividual variability, risk of hypoglycemia, or weight gain with glargine.Insulin degludec (Tresiba) is an ultra-long-acting insulin that can last in the body for up to 42 hours, although it is generally still ...
(NPH, detemir, or glargine) Premixed (30/70, 50/50 or 25/75) Short acting (Regular human, lispro, glulisine or aspart) 55.5±13.0 227 (52.4) 206 (47.6) 8.7±6.6 150.0±62.0 195.0±77.0 11.2±1.5 220 (51.0) 112 (26.0) 95 (22.0) 6 (1.0) Note: Values are expressed as mean ±...
The combinations insulin lispro+insulin glargineand regular+NPH have been compared in a randomized, crossover study for 32 weeks in 25 patients(6). HbA1cwas not different, but the total insulin dose was lower with insulin lispro+insulin glargine and there were fewer episodes ofnocturnal hypoglycem...